This follows on from our previous extensive in vitro assessment of idasanutlin alone and in combination with chemotherapies (cisplatin, doxorubicin, topotecan, busulfan and temozolomide) in a panel of MYCN amplified and non‐amplified neuroblastoma cell lines.10 The intermittent dosing schedule tested showed that both RO6839921 alone and in combination with temozolomide were well tolerated. The gene discussed is MYCN; the disease is neuroblastoma.